了解肝细胞癌诊断和治疗的肠道失生症
Jingjing Yu1, Xiaoping Chen2, Xiangliang Yang3
1Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China; Hubei Key Laboratory of Hepato-Pancreatic-Biliary Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
肠道微生物群影响肝癌 (肝细胞癌/HCC) 的进展和免疫反应. 调节肠道细菌为HCC提供了作为辅助治疗和诊断生物标志物的潜力.
科学领域:
- 胃肠病学 胃肠病学
- 在瘤学瘤学.
- 微生物学 微生物学
背景情况:
- 肠道微生物组通过肠肝循环显著影响肝细胞癌 (HCC).
- 微生物因素,如MAMP,代谢物和真菌重新编程肝脏代谢,改变肝脏的免疫微环境.
研究的目的:
- 审查肠道微生物群失生症在HCC发育和各种病因中的进展中的作用.
- 探索肠道微生物组作为早期HCC诊断和免疫治疗疗效的生物标志物的潜力.
- 讨论在HCC治疗中调节肠道微生物群的治疗策略.
主要方法:
- 对研究肠道微生物组和HCC的文献综述.
- 对将肠道失调与HCC病变发生联系起来的机制的分析.
- 检查针对肠道微生物组的当前和新兴治疗干预措施.
主要成果:
- 肠道微生物群失调有助于通过代谢和免疫变化的HCC进展.
- 特定的微生物形状与不同的HCC病因有关.
- 肠道微生物组显示为HCC检测和治疗反应的非侵入性生物标志物具有前途.
结论:
- 准肠道微生物组代表了对HCC的有希望的辅助治疗策略.
- 通过饮食,益生菌,FMT和纳米输送系统进行微生物组调节,需要进一步研究HCC管理.
- 了解肠肝轴对于推进HCC诊断和治疗至关重要.
更多相关视频
08:40A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties
Published on: August 7, 2020
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
相关概念视频
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
What is Monogastric Digestion?
